744 related articles for article (PubMed ID: 20886718)
21. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
[TBL] [Abstract][Full Text] [Related]
23. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
[TBL] [Abstract][Full Text] [Related]
24. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
25. Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
Arumugam JR; Bommannan K; Radhakrishnan V; Sagar TG; Sundersingh S
Leuk Lymphoma; 2022 Mar; 63(3):644-652. PubMed ID: 34727819
[TBL] [Abstract][Full Text] [Related]
26. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
[TBL] [Abstract][Full Text] [Related]
27. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?
Sędek Ł; Bulsa J; Sonsala A; Twardoch M; Wieczorek M; Malinowska I; Derwich K; Niedźwiecki M; Sobol-Milejska G; Kowalczyk JR; Mazur B; Szczepański T
Cytometry B Clin Cytom; 2014 Sep; 86(5):329-39. PubMed ID: 24845957
[TBL] [Abstract][Full Text] [Related]
28. Immunophenotypic aberrancies in acute lymphoblastic leukemia from 282 Iraqi patients.
Jalal SD; Al-Allawi NAS; Al Doski AAS
Int J Lab Hematol; 2017 Dec; 39(6):625-632. PubMed ID: 28722319
[TBL] [Abstract][Full Text] [Related]
29. [Comparison of the immunophenotype of patients with B lineage acute lymphoblastic leukemia at diagnosis and relapse].
Liu YR; Chang Y; Fu JY; Cheng YF; Zhang LP; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):335-8. PubMed ID: 16875586
[TBL] [Abstract][Full Text] [Related]
30. CD19 negative precursor B acute lymphoblastic leukemia (B-ALL)-Immunophenotypic challenges in diagnosis and monitoring: A study of three cases.
Ghodke K; Bibi A; Rabade N; Patkar N; Subramanian PG; Kadam PA; Badrinath Y; Ghogale S; Gujral S; Tembhare P
Cytometry B Clin Cytom; 2017 Jul; 92(4):315-318. PubMed ID: 27018867
[TBL] [Abstract][Full Text] [Related]
31. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
32. [The limited possibility of using a simplified approach to detect minimal residual disease by the flow cytometry technique in children with precursor B-lineage acute lymphoblastic leukemia].
Popov AM; Verzhbitskaia T; Tsaur GA; Shorikov EV; Tsvirenko SV; Savel'ev LI; Fechina LG
Klin Lab Diagn; 2011 Mar; (3):25-9. PubMed ID: 21574456
[TBL] [Abstract][Full Text] [Related]
33. 15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
Chatterjee G; Dhende P; Raj S; Shetty V; Ghogale S; Deshpande N; Girase K; Patil J; Kalra A; Narula G; Dalvi K; Dhamne C; Moulik NR; Rajpal S; Patkar NV; Banavali S; Gujral S; Subramanian PG; Tembhare PR
Eur J Haematol; 2024 Jan; 112(1):122-136. PubMed ID: 37706583
[TBL] [Abstract][Full Text] [Related]
34. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease.
Dworzak MN; Fröschl G; Printz D; Zen LD; Gaipa G; Ratei R; Basso G; Biondi A; Ludwig WD; Gadner H
Leukemia; 2004 Apr; 18(4):703-8. PubMed ID: 14961034
[TBL] [Abstract][Full Text] [Related]
35. Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Iwamoto S; Deguchi T; Ohta H; Kiyokawa N; Tsurusawa M; Yamada T; Takase K; Fujimoto J; Hanada R; Hori H; Horibe K; Komada Y
Int J Hematol; 2011 Aug; 94(2):185-192. PubMed ID: 21800074
[TBL] [Abstract][Full Text] [Related]
36. Lymphoblastic lymphoma.
Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
[TBL] [Abstract][Full Text] [Related]
37. Implementation of a simplified flow cytometric assays for minimal residual disease monitoring in childhood acute lymphoblastic leukemia.
Vinhas E; Lucena-Silva N; Pedrosa F
Cytometry B Clin Cytom; 2018 Jan; 94(1):94-99. PubMed ID: 27342632
[TBL] [Abstract][Full Text] [Related]
38. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
39. The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia.
Setiadi A; Owen D; Tsang A; Milner R; Vercauteren S
Int J Lab Hematol; 2016 Oct; 38(5):527-34. PubMed ID: 27339737
[TBL] [Abstract][Full Text] [Related]
40. B-lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting.
Mikhailova E; Itov A; Zerkalenkova E; Roumiantseva J; Olshanskaya Y; Karachunskiy A; Novichkova G; Maschan M; Popov A
Cytometry B Clin Cytom; 2022 Sep; 102(5):353-359. PubMed ID: 35796438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
